Bone Matrix Composition Following PTH Treatment is Not Dependent on Sclerostin Status

详细信息    查看全文

• 作者：Ryan D. Ross ; Maleeha Mashiatulla ; Alexander G. Robling…
• 关键词：Mineralization ; Bone quality ; Matrix composition ; Sclerostin ; Parathyroid hormone
• 刊名：Calcified Tissue International
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：98
• 期：2
• 页码：149-157
• 全文大小：802 KB
• 参考文献：1.Acerbo AS, Carr GL, Judex S, Miller LM (2012) Imaging the material properties of bone specimens using reflection-based infrared microspectroscopy. Anal Chem 84:3607–3613PubMedCentral CrossRef PubMed
  2.Atkins GJ, Rowe PS, Lim HP, Welldon KJ, Ormsby R, Wijenayaka AR, Zelenchuk L, Evdokiou A, Findlay DM (2011) Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res 26:1425–1436PubMedCentral CrossRef PubMed
  3.Bellido T (2006) Downregulation of SOST/sclerostin by PTH: a novel mechanism of hormonal control of bone formation mediated by osteocytes. J Musculoskelet Neuronal Interact 6:358–359PubMed
  4.Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25:1468–1486CrossRef PubMed
  5.Burr DB (2002) Bone material properties and mineral matrix contributions to fracture risk or age in women and men. J Musculoskelet Neuronal Interact 2:201–204PubMed
  6.Cheng Z, Yao W, Zimmermann EA, Busse C, Ritchie RO, Lane NE (2009) Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats. J Bone Miner Res 24:209–220PubMedCentral CrossRef PubMed
  7.de Paula FJ, Rosen CJ (2010) Back to the future: revisiting parathyroid hormone and calcitonin control of bone remodeling. Horm Metab Res 42:299–306CrossRef PubMed
  8.Felsenberg D, Boonen S (2005) The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther 27:1–11CrossRef PubMed
  9.Hassler N, Roschger A, Gamsjaeger S, Kramer I, Lueger S, van Lierop A, Roschger P, Klaushofer K, Paschalis EP, Kneissel M, Papapoulos S (2014) Sclerostin deficiency is linked to altered bone composition. J Bone Miner Res 29:2144–2151CrossRef PubMed
  10.Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688–703CrossRef PubMed
  11.Keller H, Kneissel M (2005) SOST is a target gene for PTH in bone. Bone 37:148–158CrossRef PubMed
  12.Kneissel M, Boyde A, Gasser JA (2001) Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH (1-34). Bone 28:237–250CrossRef PubMed
  13.Kogawa M, Wijenayaka AR, Ormsby R, Thomas GP, Anderson PH, Bonewald LF, Findlay DM, Atkins GJ (2013) Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2. J Bone Miner Res 28:2436–2448CrossRef PubMed
  14.Kramer I, Loots GG, Studer A, Keller H, Kneissel M (2010) Parathyroid hormone (PTH) induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 25:178–189PubMedCentral CrossRef PubMed
  15.Krempien B, Friedrich E, Ritz E (1978) Effect of PTH on osteocyte ultrastructure. Adv Exp Med Biol 103:437–450CrossRef PubMed
  16.Li X, Ominsky M, Niu Q, Sun N, Daugherty B, D’Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Paszty C, Ke HZ, Simonet WS (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23:860–869CrossRef PubMed
  17.Lombardi G, Di Somma C, Rubino M, Faggiano A, Vuolo L, Guerra E, Contaldi P, Savastano S, Colao A (2011) The roles of parathyroid hormone in bone remodeling: prospects for novel therapeutics. J Endocrinol Invest 34:18–22PubMed
  18.Miller LM, Little W, Schirmer A, Sheik F, Busa B, Judex S (2007) Accretion of bone quantity and quality in the developing mouse skeleton. J Bone Miner Res 22:1037–1045CrossRef PubMed
  19.Misof BM, Paschalis EP, Blouin S, Fratzl-Zelman N, Klaushofer K, Roschger P (2010) Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate. J Bone Miner Res 25:2297–2303CrossRef PubMed
  20.Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, Dempster DW, Nieves J, Shane E, Fratzl P, Klaushofer K, Bilezikian J, Lindsay R (2003) Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 88:1150–1156CrossRef PubMed
  21.Mosekilde L, Melsen F (1978) A tetracycline-based histomorphometric evaluation of bone resorption and bone turnover in hyperthyroidism and hyperparathyroidism. Acta Med Scand 204:97–102CrossRef PubMed
  22.Ota K, Quint P, Ruan M, Pederson L, Westendorf JJ, Khosla S, Oursler MJ (2013) Sclerostin is expressed in osteoclasts from aged mice and reduces osteoclast-mediated stimulation of mineralization. J Cell Biochem 114:1901–1907PubMedCentral CrossRef PubMed
  23.Padhi D, Allison M, Kivitz AJ, Gutierrez MJ, Stouch B, Wang C, Jang G (2013) Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study. J Clin Pharmacol 54:168–178CrossRef PubMed
  24.Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19–26CrossRef PubMed
  25.Padhi D, Stouch B, Jang G, Fang L, Darling M, Glise H, Robinson M, Harris S, Posvar E (2007) Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women. J Bone Miner Res 22:S37
  26.Paschalis EP, Burr DB, Mendelsohn R, Hock JM, Boskey AL (2003) Bone mineral and collagen quality in humeri of ovariectomized cynomolgus monkeys given rhPTH (1-34) for 18 months. J Bone Miner Res 18:769–775CrossRef PubMed
  27.Paschalis EP, Glass EV, Donley DW, Eriksen EF (2005) Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial. J Clin Endocrinol Metab 90:4644–4649CrossRef PubMed
  28.Recker R, Benson C, Matsumoto T, Bolognese M, Robins D, Alam J, Chiang AY, Hu L, Krege JH, Sowa H, Mitlak B, Myers S (2014) A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res 30:216–224CrossRef
  29.Robling AG, Kedlaya R, Ellis SN, Childress PJ, Bidwell JP, Bellido T, Turner CH (2011) Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in Sost-deficient mice. Endocrinology 152:2963–2975PubMedCentral CrossRef PubMed
  30.Roschger P, Paschalis EP, Fratzl P, Klaushofer K (2008) Bone mineralization density distribution in health and disease. Bone 42:456–466CrossRef PubMed
  31.Ross RD, Edwards LH, Acerbo AS, Ominsky MS, Virdi AS, Sena K, Miller LM, Sumner DR (2014) Bone matrix quality following sclerostin antibody treatment. J Bone Miner Res 29:1597–1607CrossRef PubMed
  32.Tazawa K, Hoshi K, Kawamoto S, Tanaka M, Ejiri S, Ozawa H (2004) Osteocytic osteolysis observed in rats to which parathyroid hormone was continuously administered. J Bone Miner Metab 22:524–529CrossRef PubMed
  33.van Bezooijen RL, ten Dijke P, Papapoulos SE, Lowik CW (2005) SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 16:319–327CrossRef PubMed
  
• 作者单位：Ryan D. Ross (1)
  Maleeha Mashiatulla (1) (2)
  Alexander G. Robling (4) (5)
  Lisa M. Miller (6) (7)
  D. Rick Sumner (1) (2) (3)
  
  1. Department of Anatomy and Cell Biology, Rush University Medical Center, 600 South Paulina, Suite 507, Chicago, IL, 60612, USA
  2. Department of Bioengineering, University of Illinois Chicago, Chicago, IL, USA
  4. Department of Anatomy and Cell Biology, Indiana University, Indianapolis, IN, USA
  5. Richard L. Roudebush VA Medical Center, Indianapolis, IN, USA
  6. Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY, USA
  7. National Synchrotron Light Source-II, Brookhaven National Laboratory, Upton, NY, USA
  3. Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL, USA
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Life Sciences
  Biochemistry
  Endocrinology
  Orthopedics
  Cell Biology
  
• 出版者：Springer New York
• ISSN：1432-0827

文摘

Sclerostin and parathyroid hormones are strong negative and positive regulators of bone formation, respectively. The anabolic response induced by intermittent (iPTH) treatment is sclerostin status-dependent. However, the interaction between sclerostin and iPTH at the matrix level is unknown. The goal of the current study was to determine if iPTH treatment affects matrix composition and, if so, whether these effects are dependent on sclerostin status. Humeral trabecular and cortical bone sites from 16 week old male wild-type (WT) and sclerostin knockout (KO) mice, which had been treated with vehicle or iPTH from age 10–16 weeks, were examined by micro-computed tomography (µCT) to measure bone volume, backscatter scanning electron microscopy (bSEM) to assess global mineralization, and Fourier transform infrared microspectroscopy (FTIRM) to examine matrix composition (mineral-to-matrix ratio, crystallinity, collagen cross-link ratio, and carbonate substitution). The FTIRM measurements were restricted to the tissue formed during the 6-week treatment period. iPTH treatment led to increased trabecular bone volume (p < 0.001) and this effect was much greater in KO mice than WT mice (interaction effect, p < 0.001). iPTH treatment led to reduced trabecular crystallinity (p = 0.047), increased cortical bone area (p < 0.001), decreased cortical bone crystallinity (p = 0.002) and increased cortical bone collagen cross-linking (p = 0.028) to similar degrees in both WT and KO mice. Compared to WT mice, sclerostin KO mice had higher trabecular and cortical bone mass (p < 0.001) and lower mineral-to-matrix ratio in the trabecular (p = 0.010) and cortical (p = 0.016) compartments. Thus, iPTH-induced changes in bone mass are dependent upon sclerostin status in the trabecular compartment, but not in the cortical compartment. In contrast, iPTH-induced changes in matrix composition are sclerostin-independent in both trabecular and cortical compartments.